Uric acid as a biomarker in patients with COPD and CKD
Folia Medica · 17.06.2026 · 68 (3)
DOI: 10.3897/folmed.68.e190088 ↗Kurz gefasst
Fachartikel in der Zeitschrift Folia Medica, online erschienen am 17.06.2026. Verfasst von Elena D Borisova und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology and Phtysiology, Medical University of Pleven, Pleven, Bulgaria. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Renal Insufficiency, Chronic, Uric Acid. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: COPD
Abstract (Originalsprache)
Introduction
High uric acid level is a risk factor for the development of CKD. It is also a biomarker associated with exacerbations, severity, and progression of COPD.
Aim
To investigate the role of uric acid in the development of CKD in patients with COPD. Materials and methods : This was a prospective study of 90 outpatients with stable COPD, conducted over two visits between June 2023 and January 2025. The patients were divided into two groups: one group had COPD with CKD, and the other had COPD without CKD, as determined by their glomerular filtration rate (eGFR). The study investigated the relationship between elevated uric acid levels and the presence of CKD in COPD patients. The data was processed using SPSS, version 20.0. A p -value <0.05 was considered statistically significant.
Results
Forty-two and two-tenths percent of patients had COPD and CKD at the first visit, increasing to 52.6% at the second. An inverse correlation between serum uric acid levels and eGFR was identified ( p =0.010). A statistically significant difference was found between the two groups with respect to elevated uric acid levels. In the group with eGFR<60 mL/min/1.73 m 2 , 62.5% of patients had hyperuricemia ( p =0.007). A statistically significant difference was also observed in the mean serum uric acid levels between patients with and without CKD: 442.95 µmol/L versus 376.4 µmol/L, respectively ( p =0.003). During dynamic follow-up of serum uric acid levels, a statistically significant difference between the groups with and without CKD was also established ( p =0.04).
Conclusion
Elevated uric acid levels are a risk factor for the development of CKD in patients with COPD, serving as a biomarker with moderate sensitivity but low specificity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonology and Phtysiology, Medical University of Pleven, Pleven, Bulgaria.
- Department of Propaedeutics of Internal Diseases, Medical University of Pleven, Pleven, Bulgaria.
Zitieren
APA
Borisova, E. D., Ivankovska, S. T., Pavlov, P. S., & Glogovska, P. T. (2026). Uric acid as a biomarker in patients with COPD and CKD. Folia Medica, 68(3). https://doi.org/10.3897/folmed.68.e190088
Vancouver
Borisova ED, Ivankovska ST, Pavlov PS, Glogovska PT. Uric acid as a biomarker in patients with COPD and CKD. Folia Medica. 2026;68(3). doi:10.3897/folmed.68.e190088
BibTeX
@article{Borisova2026,
author = {Borisova, Elena D and Ivankovska, Snezhanka T and Pavlov, Plamen S and Glogovska, Pavlina T},
title = {Uric acid as a biomarker in patients with COPD and CKD},
journal = {Folia Medica},
year = {2026},
volume = {68},
number = {3},
doi = {10.3897/folmed.68.e190088}
}
EUVIMED